<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pmedpharm</journal-id><journal-title-group><journal-title xml:lang="ru">Фармация и фармакология</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacy &amp; Pharmacology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2307-9266</issn><issn pub-type="epub">2413-2241</issn><publisher><publisher-name>Pyatigorsk Medical and Pharmaceutical Institute - branch of Volgograd State Medical Univer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.19163/2307-9266-2019-7-2-90-96</article-id><article-id custom-type="elpub" pub-id-type="custom">pmedpharm-364</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАКОЛОГИЯ И КЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACOLOGY AND CLINICAL PHARMACOLOGY</subject></subj-group></article-categories><title-group><article-title>ВЛИЯНИЕ ЭКСТРАКТА ЖИРНОГО МАСЛА ИЗ СЕМЯН ЧЕРНУШКИ ДАМАССКОЙ (NIGELLA DAMASCENA L.) НА ЛИПИДНЫЙ СПЕКТР КРЫС ПРИ МОДЕЛИРОВАННОЙ ДИСЛИПИДЕМИИ</article-title><trans-title-group xml:lang="en"><trans-title>EFFECT OF FATTY OIL EXTRACT FROM SEEDS OF NIGELLA DAMASCENA L. ON LIPID SPECTRUM IN RATS WITH SIMULATED DYSLIPIDEMIA</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ефремова</surname><given-names>М. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Efremova</surname><given-names>M. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ефремова Марина Павловна – преподаватель кафедры фармакологии с курсом клинической фармакологии</p><p>357532, г. Пятигорск, пр. Калинина, 11</p></bio><bio xml:lang="en"><p>Marina P. Efremova – Lecturer of the Department of Pharmacology with the course of Clinical Pharmacology</p><p>11, Kalinin ave., Pyatigorsk, Russia, 357532</p></bio><email xlink:type="simple">efremova.marinka26@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Пятигорский медико-фармацевтический институт – филиал ФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pyatigorsk Medical and Pharmaceutical Institute – branch of Volgograd State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>11</day><month>05</month><year>2019</year></pub-date><volume>7</volume><issue>2</issue><fpage>90</fpage><lpage>96</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ефремова М.П., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Ефремова М.П.</copyright-holder><copyright-holder xml:lang="en">Efremova M.P.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmpharm.ru/jour/article/view/364">https://www.pharmpharm.ru/jour/article/view/364</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Провести исследование по определению липидного спектра плазмы крови и печени у крыс при моделированной дислипидемии на фоне введения экстракта жирного масла из семян чернушки дамасской.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В работе использовались лабораторные животные – крысы самцы линии Wistar. Для изучения гиполипидемической активности использовали такие модели как – острую твиновую, субхроническую Д2-витаминную модели и модель хронической сердечной недостаточности. Определяемыми параметрами служили концентрация холестерина и триглицеридов в сыворотке крови и печени, а также концентрация атерогенных и неатнрогенных липопротеидов в сыворотке крови, и коэффициент атерогенности.</p></sec><sec><title>Результаты</title><p>Результаты. В результате исследования было установлено, что курсовое введение экстракта жирного масла из семян чернушки дамасской на фоне моделированной хронической сердечной недостаточности (ХСН) по правожелудочковому типу, нормализует липидный спектр сыворотки крови экспериментальных животных, вызывая увеличение концентрации липопротеидов высокой плотности (не атерогенных), и снижает концентрацию липопротеидов низкой плотности (атерогенных). Однократное введение экстракта жирного масла из семян чернушки дамасской способствует коррекции нарушений липидного обмена в условиях острой твиновой липидопатии, в то время как курсовое применение изучаемого объекта снижает концентрацию холестерина и триглицеридов печени, и сыворотки крови в условиях субхронической дислипидемии. При этом эффект от применения экстракта жирного масла из семян чернушки дамасской не уступал таковому у препарата сравнения «Омакор».</p></sec><sec><title>Заключение</title><p>Заключение. Возможность применения экстракта жирного масла из семян чернушки дамасской в профилактических и лечебных целях при сердечнососудистых патологиях.</p></sec></abstract><trans-abstract xml:lang="en"><p>The aim of the study is to determine a lipid spectrum of blood plasma and liver in rats in with simulated dyslipidemia against the background of the administration of the fatty oil extract from the seeds of Nigella damascena L.</p><sec><title>Materials and methods</title><p>Materials and methods. Laboratory animals – Wistar male rats – were used in the work. To study the hypolipidemic activity, such models as acute Tween, subchronic vitamin-D2 models and a model of chronic heart failure were used. The identifiable parameters were the concentration of cholesterol and triglycerides in the blood serum and liver, as well as the concentration of atherogenic and non-atherogenic lipoproteins in the blood serum, and the atherogenic coefficient.</p></sec><sec><title>Results</title><p>Results. As a result of the study, it was found out that a course administration of the fatty oil extract from the seeds of Nigella damascena L. against the background of simulated chronic heart failure (CHF) by the right ventricular type, normalizes the lipid spectrum of the experimental animals’ blood serum, causing an increase in the concentration of high-density (non-atherogenic) lipoproteins, and reduces the concentration of low-density (atherogenic) lipoproteins. A single administration of the fatty oil extract from the seeds of Nigella damascena L. promotes the correction of lipid metabolism disorders under the conditions of acute Tween lipidopathy, while the direction of the object being studied reduces the concentration of cholesterol and triglycerides in the liver and blood serum under the conditions of subchronic dyslipidemia. At the same time, the effect of the use of the fatty oil extract from the seeds of Nigella damascena L. was not inferior to “Omaсor”, the reference drug.</p></sec><sec><title>Conclusion</title><p>Conclusion. The possibility of using a fatty oil extract from the seeds of Nigella damascena L. for preventive and therapeutic aims in cardiovascular diseases has been established.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>дислипидемия</kwd><kwd>чернушка дамасская</kwd><kwd>Омакор</kwd><kwd>холестерин</kwd><kwd>хроническая сердечная недостаточность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>dyslipidemia</kwd><kwd>Nigella damascena L.</kwd><kwd>Omaсor</kwd><kwd>cholesterol</kwd><kwd>chronic heart failure</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Schedlbauer A., Davies P., Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev. 2010. – Vol. 3. CD004371. DOI:10.1002/14651858.CD004371.pub3</mixed-citation><mixed-citation xml:lang="en">Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev. 2010;3. CD004371. DOI: 10.1002/14651858.CD004371.pub3.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf S, Reddy S, Ôunpuu S, Anand S. Global burden of cardiovascular diseases, Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies // Circulation. – 2001. – Vol. 104, №23. – P. 2855–2864.</mixed-citation><mixed-citation xml:lang="en">Yusuf S, Reddy S, Ôunpuu S, Anand S. Global burden of cardiovascular diseases, Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation. 2001;104(23): 2855–64.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Cooper A., Nherera L., Calvert N., O’Flynn N., Turnbull N., Robson J., et al. Clinical guidelines and evidence review for lipid modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners. – 2008. – 236 р. DOI: 10.1136/bmj.39554.624086.AD</mixed-citation><mixed-citation xml:lang="en">Cooper A, Nherera L, Calvert N, O’Flynn N, Turnbull N, Robson J, et al. Clinical guidelines and evidence review for lipid modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners. 2008: 1-236. DOI: 10.1136/bmj.39554.624086.AD</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. – Cochrane Database Syst Rev. – 2013. – Vol. 1. – P. CD004816. DOI: 10.1002/14651858.CD004816.pub5.</mixed-citation><mixed-citation xml:lang="en">Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD004816. DOI: 10.1002/14651858.CD004816.pub4.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Scottish Intercollegiate Guidelines Network (SIGN) Risk estimation and the prevention of cardiovascular disease. A national clinical guideline. 2007.</mixed-citation><mixed-citation xml:lang="en">Scottish Intercollegiate Guidelines Network (SIGN). Risk estimation and the prevention of cardiovascular disease. Edinburgh: SIGN; 2017. (SIGN publication no. 149). [July 2017]. Available from URL: http://www.sign.ac.uk</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Moßhammer D, Schaeffeler E, Schwab M, Mörike K. Mechanisms and assessment of statin-related muscular adverse effects // Br J Clin Pharmacol. – 2014. – Vol. 78, №3. – P. 454–466. DOI: 10.1111/bcp.12360</mixed-citation><mixed-citation xml:lang="en">Moßhammer D, Schaeffeler E, Schwab M, Mörike K. Mechanisms and assessment of statin-related muscular adverse effects. Br J Clin Pharmacol.2014;78(3):454-66. DOI: 10.1111/bcp.12360</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Penumetcha M, Song M, Merchant N, Parthasarathy S. Pretreatment with n-6 PUFA protects against subsequent high fat diet induced atherosclerosis--potential role of oxidative stress-induced antioxidant defense // Atherosclerosis. – 2011. – Vol. 220, №1. – P. 53–58. DOI: 10.1016/j.atherosclerosis.2011.10.001</mixed-citation><mixed-citation xml:lang="en">Penumetcha M, Song M, Merchant N, Parthasarathy S. Pretreatment with n-6 PUFA protects against subsequent high fat diet induced atherosclerosis--potential role of oxidative stress-induced antioxidant defense. Atherosclerosis. 2011; 220(1):53-8. DOI:10.1016/j.atherosclerosis.2011.10.001</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zehr KR, Walker MK. Omega-3 polyunsaturated fatty acids improve endothelial function in humans at risk for atherosclerosis: A review // Prostaglandins Other Lipid Mediat. – 2017. – Vol. 134. – P. 131– 140. DOI:10,1016/j.prostaglandins.2017.07.005</mixed-citation><mixed-citation xml:lang="en">Zehr KR, Walker MK. Omega-3 polyunsaturated fatty acids improve endothelial function in humans at risk for atherosclerosis: A review. Prostaglandins Other Lipid Mediat. 2018 Jan;134:131-40. doi: 10.1016/j.prostaglandins.2017.07.005. Epub 2017 Aug 9.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Маширова, С.Ю., Изучение компонентного состава липидов семян чернушки посевной и чернушки дамасской / С.Ю. Маширова, Т.В. Орловская // Научные ведомости БелГУ. Серия: Медицина. Фармация. – 2012. – №4 (123). – С. 223–227.</mixed-citation><mixed-citation xml:lang="en">Mashirova SY, Orlovskaya TV. Izucheniye komponentnogo sostava lipidov semyan chernushki posevnoy i chernushki damasskoy [Examination of lipid component of the Nigella Sativa and Nigella Damascena seeds]. Belgorod State University scientific journal. Series. Medicine. Pharmacy. 2012; 17(4): 223-6. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Альтернативы биомедицины .Т. 2. Классика и альтернативы фармакотоксикологии / Н.Н. Каркищенко. – М.: Изд-во ВПК, 2007. – 448 с.</mixed-citation><mixed-citation xml:lang="en">Karkischenko NN. Al’ternativy biomeditsiny Tom 2. Klassika i al’ternativy farmakotoksikologii [Biomedicine alternatives. Part 2. Basic principles of biomedicine and pharmacomodeling]. Moscow: VPC: 2007; 448. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Альтернативы биомедицины .Т. 1. Основы биомедицины и фармакомоделирования. / Н.Н. Каркищенко – М.: Изд-во ВПК., 2007. – 320 с.</mixed-citation><mixed-citation xml:lang="en">Karkischenko NN. Al’ternativy biomeditsiny Tom 1. Klassika i al’ternativy farmakotoksikologii [Biomedicine alternatives. Part 1. Basic principles of biomedicine and pharmacomodeling]. Moscow: VPC: 2007: 320. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Полякова, Э.Д. Гиперлипидемия, вызванная введением тритона WR – 1339 / Э.Д. Полякова, М.А. Климова // Пат. физиология и эксперим. терапия. – 1973. – №1. – С. 74–77.</mixed-citation><mixed-citation xml:lang="en">. Polyakova ED, Klimov MA. Giperlipidemiya, vyzvannaya vvedeniyem tritona WR – 1339 [Hyperlipidemia caused by the introduction of the Triton WR – 1339]. Pat. physiology and experimentation. therapy. 1973;1:74-7. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Витамин С: Химия и биохимия / М. Девис, Дж. Остин, Д. Патридж. М.: Мир, 1999. – 52 с.</mixed-citation><mixed-citation xml:lang="en">Davis M, Austin Dj, Patridge М. Vitamin S: Khimiya i biokhimiya [Vitamin C: Chemistry and Biochemistry]. Mir: 1999:52. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Пятницкий, Н.Н., Блинков Ю.А. К вопросу о моделировании недостаточности правого сердца / Н.Н. Пятницкий, Ю.А. Блинков // Кардиология. – 1970. – №1. – С. 143–144.</mixed-citation><mixed-citation xml:lang="en">Pyatnitsky NN, Blinkov YuA. K voprosu o modelirovanii nedostatochnosti pravogo serdtsa [On the issue of modeling right heart failure]. Cardiology. 1970;1:143-4. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Федоров, В.Н. Динамическая модель тотальной хронической сердечной недостаточности у крыс / В.Н. Федоров, А. Д. Ноздрачев, Е.В Сальников // Вестн. С.-Пб. ун-та. – 2006. – Сер. 3. – Вып. 2. – С. 103–107.</mixed-citation><mixed-citation xml:lang="en">Fedorov VN, Nozdrachev AD, Salnikov EV. Dinamicheskaya model’ total’noy khronicheskoy serdechnoy nedostatochnosti u krys [Dynamic model of rat’s total chronic heart failure]. Reporter of Saint Petersburg University. 2006; Ser. 3: Release 2:103-7. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Обмен липидов и липопротеидов и его нарушения / А.Н. Климов, Н.Г. Никульчева – СПб.: Питер Ком, 1999. – 512 с.</mixed-citation><mixed-citation xml:lang="en">Klimov AN, Nikulcheva NG. Obmen lipidov i lipoproteidov i yego narusheniya [Lipid and lipoprotein metabolism and its disorders]. SPb.: Piter Kom. 1999: 512. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Lyons C., Kennedy E., Roche H. Metabolic inflammation-differential modulation by dietary constituents // Nutrients. – 2016. – Vol. 8. – P. 247. DOI: 10.3390/nu8050247.</mixed-citation><mixed-citation xml:lang="en">Lyons C, Kennedy E, Roche H. Metabolic inflammation-differential modulation by dietary constituents // Nutrients. 2016;8(5)247. DOI: 10.3390/nu8050247.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Возможности индивидуализации оценки атерогенности липопротеинового спектра крови / Н.Г. Плехова, В.А. Невзорова, Л.В. Родионова [и др.] // Современные проблемы науки и образования. – 2016. – № 4.</mixed-citation><mixed-citation xml:lang="en">Plekhova NG, Nevzorova VA, Rodionova LV, Repinа NI, Bogdanov DU, Kulakova NV, Mokshina MV, Brodskaya TV. Vozmozhnosti individualizatsii otsenki aterogennosti lipoproteinovogo spektra krovi [Features of individualization assessing the atherogenic lipoprotein blood spectrum]. Modern problems of science and education. 2016;4: 98. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kovar J., Fejfarova V., Pelikanova T., Poledne R. Hyperglycemia downregulates total lipoprotein lipase activity in humans. // Physiol. Res. – 2004. – Vol. 53. – P. 61–68.</mixed-citation><mixed-citation xml:lang="en">Kovar J, Fejfarova V, Pelikanova T, Poledne R. Hyperglycemia downregulates total lipoprotein lipase activity in humans. Physiol. Res. 2004; 61-68.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Руководство по проведению доклинических исследований лекарственных средств / под ред. А.Н Миронова.Часть 1. – М.: Гриф и К, 2012. – 944 с.</mixed-citation><mixed-citation xml:lang="en">Mironov AN. Rukovodstvo po provedeniyu doklinicheskikh issledovaniy lekarstvennykh sredstv [Medicinal product preclinical research execution guidance]. Part one. Moscow: Grif i K: 2012; 944. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Каменев, В.Ф. Влияние лёгких на липидный профиль в коронарных артериях у больных с хронической сердечной недостаточностью, возникшей на фоне ишемической болезни сердца / В.Ф. Каменев, И.Л. Стрельникова, Н.И. Оболонкова // Научные ведомости Белгородского государственного университета. Серия: Медицина. Фармация. – 2012. – Т. 17. – №. 4. – С. 77–80.</mixed-citation><mixed-citation xml:lang="en">Kamenev VF, Strelnikova IL, Obolonkova NI. Vliyaniye logkikh na lipidnyy profil’ v koronarnykh arteriyakh u bol’nykh s khronicheskoy serdechnoy nedostatochnost’yu, voznikshey na fone ishemicheskoy bolezni serdtsa [Comparative characteristics of lipids profil of aorta and veins in patients with chronic cardiac i nsufficiency caused by ischemic heart disease]. Belgorod State University scientific journal. Series. Medicine. Pharmacy. 2012;4: 77-80. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Обрезан, А.Г. Нейрогуморальный дисбаланс при хронической сердечной недостаточности: классические и современные позиции / А.Г. Обрезан, Н.В. Куликов // Российский кардиологический журнал. – 2017. – №. 9. (149). – С. 83–92. DOI: 10.15829/1560-4071-2017-9-83-92</mixed-citation><mixed-citation xml:lang="en">Obrezan AG, Kulikov NV. Neyrogumoral’nyy disbalans pri khronicheskoy serdechnoy nedostatochnosti: klassicheskiye i sovremennyye pozitsii. [Neuro-humoral disbalance in chronic heart failure: classic and modern perspectives]. Russian Journal of Cardiology. 2017;9:83-92. DOI: 10.15829/1560-4071-2017-9-83-92. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Влияние жирного масла чернушки дамасской на липидный спектр плазмы крови крыс при моделированной хронической сердечной недостаточности / Сергиенко А.В., Ефремова М.П., Савенко И.А. [и др] // Современные наукоемкие технологии. – 2012. – № 8. – С. 42–43.</mixed-citation><mixed-citation xml:lang="en">Sergienko AV, Efremova MP, Savenko IA, Ivashev MN. Vliyaniye zhirnogo masla chernushki damasskoy na lipidnyy spektr plazmy krovi krys pri modelirovannoy khronicheskoy serdechnoy nedostatochnosti [The impact of Nigella damascenaessential oil on rat’s blood plasma lipid spectrum under simulated chronic heart failure]. Modern knowledge-intensive technologies. 2012;8: 42-3. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Xu J., Zhu L., Liu H., et al. Thymoquinone reduces cardiac damage caused by hypercholesterolemia in apolipoprotein E-deficient mice // Lipids Health Dis. – 2018. – Vol. 17, №1. – P. 173–177. DOI: 10.1186/s12944-018-0829-y.</mixed-citation><mixed-citation xml:lang="en">Xu J, Zhu L, Liu H, et al. Thymoquinone reduces cardiac damage caused by hypercholesterolemia in apolipoprotein E-deficient mice Lipids Health Dis. 2018 Jul 26;17(1):173. DOI: 10.1186/s12944-018-0829-y.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
